Rosa Lapalombella, PhD
Leadership Title: Co-Leader, Leukemia and Hematologic Malignancies Program
Academic Title: Professor in the College of Medicine
Research Program: Leukemia and Hematologic Malignancies
Columbus, Ohio 43210-1214
About Me
More info forI am co-leader of the Leukemia and Hematologic Malignancies (LHM) program at the OSUCCC – James, where my research focus is on epigenetic alterations of cancer cells and the development of experimental therapeutics for hematologic disease. I am the co-holder of a patent for methods and compositions for delivering therapeutic agents in the treatment of B-cell-related disorders.
My work has contributed to the translation of five therapeutic agents into clinical trials for chronic lymphocytic leukemia (CLL) and has been reported in more than 40 articles in such academic journals as Cancer Discovery, Cancer Cell, Journal of Clinical Oncology, Leukemia and Blood. In addition to publications, my work has been recognized with many oral presentations at national and international conferences, including the American Society of Hematology, the Italian Society of Biology and Genetics, and the Translational Research Cancer Centers Consortium.
I am the recipient of the Department of Defense Career Development Award for young faculty and the American Cancer Society Research Scholar Award. My experience includes more than 10 grant-funded research initiatives.
Additionally, I am the associate director for basic research in the Division of Hematology and also serve as the director of the Pelotonia Fellowship Program, overseeing the peer-review process used to evaluate all student applications for Pelotonia fellowships and identifying those with the highest scientific merit for funding.
Research Interests
More info for- Glioblastoma
- Neoplasms
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Mantle-Cell
- Lymphoma
- Ischemia
Education & Training
More info forBA
- University of Bologna, Italy
Bologna, Italy
Doctorate
- University of Bologna, Italy
Bologna, Italy
- University of Bologna, Italy
Academic Office & Contact Information
More info forAcademic Office:
Comprehensive Cancer Center 0455C
410 W 12th Ave
Columbus, Ohio 43210-1214Phone:
614-685-6919Email:
lapalombella.1@osu.eduPublications
More info forSeptember 30, 2024CD37 in acute myeloid leukemia: a novel surface target for drug delivery.
Jeremy E, Artiga E, Elgamal S, Cheney CM, Eicher D, Zalponik K, Orwick S, Mao HCC, Wasmuth R, Harrington BK, Mustonen A, Beshay P, Halley P, Castro C, Williams KE, Hing ZA, Chen TL, Lucas CR, Vantangoli NJ, Lapalombella R, Grieselhuber NR, Mo XM, Hertlein E, Muthusamy N, Mundy-Bosse BL, Byrd JC, Larkin K
Blood Adv
August 8, 2024LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia.
Ravikrishnan J, Diaz-Rohena DY, Muhowski E, Mo X, Lai TH, Misra S, Williams CD, Sanchez J, Mitchell A, Satpati S, Perry E, Kaufman T, Liu C, Lozanski A, Lozanski G, Rogers K, Kittai AS, Bhat SA, Collins MC, Davids MS, Jain N, Wierda WG, Lapalombella R, Byrd JC, Tan F, Chen Y, Chen Y, Shen Y, Anthony SP, Woyach JA, Sampath D
Haematologica
March 4, 2024The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
Marr AR, Halpin M, Corbin DL, Asemelash Y, Sher S, Gordon BK, Whipp EC, Mitchell S, Harrington BK, Orwick S, Benrashid S, Goettl VM, Yildiz V, Mitchell AD, Cahn O, Mims AS, Larkin KTM, Long M, Blachly J, Woyach JA, Lapalombella R, Grieselhuber NR
Exp Hematol Oncol
December 27, 2023Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis.
Saygin C, Zhang P, Stauber J, Aldoss I, Sperling AS, Weeks LD, Luskin MR, Knepper TC, Wanjari P, Wang P, Lager AM, Fitzpatrick C, Segal JP, Gharghabi M, Gurbuxani S, Venkataraman G, Cheng JX, Eisfelder BJ, Bohorquez O, Patel AA, Umesh Nagalakshmi S, Jayaram S, Odenike OM, Larson RA, Godley LA, Arber DA, Gibson CJ, Munshi NC, Marcucci G, Ebert BL, Greally JM, Steidl U, Lapalombella R, Shah BD, Stock W
Blood Cancer Discov
June 16, 2023PRMT5 Inhibition Drives Therapeutic Vulnerability to Combination Treatment with BCL-2 Inhibition in Mantle Cell Lymphoma.
Brown-Burke F, Hwang I, Sloan SL, Hinterschied C, Helmig-Mason J, Long ME, Chan WK, Prouty A, Chung JH, Zhang Y, Singh S, Youssef Y, Bhagwat N, Chen Z, Chen-Kiang S, DiLiberto M, Elemento O, Sehgal L, Alinari L, Vaddi K, Scherle P, Lapalombella R, Paik J, Baiocchi RA
Blood Adv
June 2, 2023PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL, Brown F, Long ME, Weigel C, Koirala S, Chung JH, Pray B, Villagomez L, Hinterschied C, Sircar A, Helmig-Mason J, Prouty A, Brooks E, Youssef Y, Hanel W, Parekh S, Chan WK, Chen Z, Lapalombella R, Sehgal L, Vaddi K, Scherle P, Chen-Kiang S, Di Liberto M, Elemento O, Meydan C, Foox J, Butler D, Mason CE, Baiocchi RA, Alinari L
Blood
May 18, 2023Microenvironmental control of hematopoietic stem cell fate via CXCL8 and protein kinase C.
Binder V, Li W, Faisal M, Oyman K, Calkins DL, Shaffer J, Teets EM, Sher S, Magnotte A, Belardo A, Deruelle W, Gregory TC, Orwick S, Hagedorn EJ, Perlin JR, Avagyan S, Lichtig A, Barrett F, Ammerman M, Yang S, Zhou Y, Carson WE, Shive HR, Blachly JS, Lapalombella R, Zon LI, Blaser BW
Cell Rep
January 6, 2023Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation.
Hing ZA, Walker JS, Whipp EC, Brinton L, Cannon M, Zhang P, Sher S, Cempre CB, Brown F, Smith PL, Agostinelli C, Pileri SA, Skinner JN, Williams K, Phillips H, Shaffer J, Beaver LP, Pan A, Shin K, Gregory CT, Ozer GH, Yilmaz SA, Harrington BK, Lehman AM, Yu L, Coppola V, Yan P, Scherle P, Wang M, Pitis P, Xu C, Vaddi K, Chen-Kiang S, Woyach J, Blachly JS, Alinari L, Yang Y, Byrd JC, Baiocchi RA, Blaser BW, Lapalombella R
Nat Commun
November 14, 2022VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.
Sher S, Whipp E, Walker J, Zhang P, Beaver L, Williams K, Orwick S, Ravikrishnan J, Walker B, Perry E, Gregory C, Purcell M, Pan A, Yan P, Alinari L, Johnson AJ, Frigault MM, Greer JM, Hamdy A, Izumi R, Mo X, Sampath D, Woyach J, Blachly J, Byrd JC, Lapalombella R
Leukemia
October 26, 2022HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia.
Lai TH, Ozer HG, Gasparini P, Nigita G, Distefano R, Yu L, Ravikrishnan J, Yilmaz S, Gallegos JJ, Shukla SA, Puduvalli VK, Woyach JA, Lapalombella R, Blachly JS, Byrd JC, Sampath D
Blood Adv
September 16, 2022Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor-mediated synergistic antileukemic actions.
Zhang P, Brinton LT, Gharghabi M, Sher S, Williams K, Cannon M, Walker JS, Canfield D, Beaver L, Cempre CB, Phillips H, Chen X, Yan P, Lehman A, Scherle P, Wang M, Vaddi K, Baiocchi R, Wang R, Sampath D, Alinari L, Blachly JS, Lapalombella R
Sci Adv
May 28, 2022DNA Origami Nanostructures Elicit Dose-Dependent Immunogenicity and Are Nontoxic up to High Doses In Vivo.
Lucas CR, Halley PD, Chowdury AA, Harrington BK, Beaver L, Lapalombella R, Johnson AJ, Hertlein EK, Phelps MA, Byrd JC, Castro CE
Small
May 24, 2022Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study.
Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA
Clin Cancer Res
November 17, 2021PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia.
Goswami S, Mani R, Nunes J, Chiang CL, Zapolnik K, Hu EY, Frissora FW, Mo XM, Walker LA, Yan PS, Bundschuh R, Beaver L, Devine RD, Tsai YT, Ventura AM, Xie Z, Chen M, Lapalombella R, Walker AR, Mims AS, Larkin K, Grieselhuber NR, Bennett C, Phelps MA, Hertlein E, Behbehani GK, Vasu S, Byrd JC, Muthusamy N
Blood
November 3, 2021Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia.
Walker JS, Hing ZA, Sher S, Cronin J, Williams K, Harrington B, Skinner JN, Cempre CB, Gregory CT, Pan A, Yano M, Beaver LP, Walker BR, Labanowska JM, Heerema NA, Mrózek K, Woyach JA, Ruppert AS, Lehman A, Ozer HG, Coppola V, Yan P, Byrd JC, Blachly JS, Lapalombella R
Nat Commun
October 29, 2021Red blood cells differentiated in vitro using sequential liquid and semi-solid culture as a pre-clinical model.
Cannon M, Phillips H, Smith S, Mitchell S, Landes K, Desai P, Byrd J, Lapalombella R
Exp Hematol Oncol
September 13, 2021Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD-positive AML.
Zavorka Thomas ME, Lu X, Talebi Z, Jeon JY, Buelow DR, Gibson AA, Uddin ME, Brinton LT, Nguyen J, Collins M, Lodi A, Sweeney SR, Campbell MJ, Sweet DH, Sparreboom A, Lapalombella R, Tiziani S, Baker SD
Molecular Cancer Therapeutics
July 14, 2021Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
Sharma P, Xu J, Williams K, Easley M, Elder JB, Lonser R, Lang FF, Lapalombella R, Sampath D, Puduvalli VK
Neuro Oncol
June 29, 2021Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation.
Mitchell S, Zhang P, Cannon M, Beaver L, Lehman A, Harrington B, Sampath D, Byrd JC, Lapalombella R
J Hematol Oncol
May 21, 2021Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq.
Saygin C, Hu E, Zhang P, Sher S, Lozanski A, Doong TJ, Nicolet D, Orwick S, Labanowska J, Skinner JN, Cempre C, Kauffman T, Goettl VM, Heerema NA, Abruzzo L, Miller C, Lapalombella R, Behbehani G, Mims AS, Larkin K, Grieselhuber N, Walker A, Bhatnagar B, Bloomfield CD, Byrd JC, Lozanski G, Blachly JS
Leukemia
April 5, 2021Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.
Miller CR, Huang Y, Ruppert AS, Labanowska J, Jaglowski SM, Maddocks KJ, Rogers KA, Bhat S, Kittai AS, Grever M, Lapalombella R, Abruzzo LV, Heerema NA, Byrd JC, Hertlein EK, Woyach JA
Leukemia
March 22, 2021Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function.
Petty AJ, Dai R, Lapalombella R, Baiocchi RA, Benson DM, Li Z, Huang X, Yang Y
JCI Insight
February 4, 2021Targeting DNA damage repair functions of two histone deacetylases, HDAC8 and SIRT6, sensitizes acute myeloid leukemia to NAMPT inhibition.
Zhang P, Brinton LT, Williams K, Sher S, Orwick S, Lai TH, Mims AS, Coss CC, Kulp SK, Youssef Y, Chan WK, Mitchell S, Mustonen A, Cannon M, Phillips H, Lehman AM, Kauffman T, Beaver L, Canfield D, Grieselhuber NR, Alinari L, Sampath D, Yan P, Byrd JC, Blachly JS, Lapalombella R
Clin Cancer Res
January 15, 2021Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.
Walker JS, Hing ZA, Harrington B, Baumhardt J, Ozer HG, Lehman A, Giacopelli B, Beaver L, Williams K, Skinner JN, Cempre CB, Sun Q, Shacham S, Stromberg BR, Summers MK, Abruzzo LV, Rassenti L, Kipps TJ, Parikh S, Kay NE, Rogers KA, Woyach JA, Coppola V, Chook YM, Oakes C, Byrd JC, Lapalombella R
J Hematol Oncol
December 3, 2020TP-0903 is active in models of drug-resistant acute myeloid leukemia.
Jeon JY, Buelow DR, Garrison DA, Niu M, Eisenmann ED, Huang KM, Zavorka Thomas ME, Weber RH, Whatcott CJ, Warner SL, Orwick SJ, Carmichael B, Stahl E, Brinton LT, Lapalombella R, Blachly JS, Hertlein E, Byrd JC, Bhatnagar B, Baker SD
JCI Insight
October 19, 2020Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
Brinton LT, Zhang P, Williams K, Canfield D, Orwick S, Sher S, Wasmuth R, Beaver L, Cempre C, Skinner J, Cannon M, Govande M, Harrington B, Lehman A, Byrd JC, Lapalombella R, Blachly JS
J Hematol Oncol
September 14, 2020Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma.
Youssef Y, Karkhanis V, Chan WK, Jeney F, Canella A, Zhang X, Sloan S, Prouty A, Helmig-Mason J, Tsyba L, Hanel W, Zheng X, Zhang P, Chung JH, Lucas DM, Kauffman Z, Larkin K, Strohecker AM, Ozer HG, Lapalombella R, Zhou H, Xu-Monette ZY, Young KH, Han R, Nurmemmedov E, Nuovo G, Maddocks K, Byrd JC, Baiocchi RA, Alinari L
Haematologica
June 14, 2020Selinexor for advanced hematologic malignancies.
Walker JS, Garzon R, Lapalombella R
Leuk Lymphoma
June 14, 2020Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia.
Brinton LT, Sher S, Williams K, Canfield D, Orwick S, Wasmuth R, Cempre C, Skinner J, Lehman A, Blachly JS, Byrd JC, Lapalombella R
Cancers (Basel)
June 10, 2020Recognition of nuclear export signals by CRM1 carrying the oncogenic E571K mutation.
Baumhardt JM, Walker JS, Lee Y, Shakya B, Brautigam CA, Lapalombella R, Grishin N, Chook YM
Mol Biol Cell